What Is Chronic Lymphocytic Leukemia?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Chronic lymphocytic leukemia (CLL) is a cancer of the blood in which too many lymphocytes, a type of white blood cell, are produced by the bone marrow and by organs of the lymph system. Lymphocytes normally fight infection by making antibodies that attack foreign proteins.

CLL is the most common adult leukemia. About 15,110 new cases of CLL will be diagnosed in the United States in 2008, according to the American Cancer Society. The disease usually occurs in individuals between 65 and 80 years old.

If you have CLL, your lymphocytes are overabundant and many are immature. They are not able to fight infections. They crowd out other blood cells and may collect in blood, bone marrow, lymph tissue, and spleen. CLL is a slowly progressing disease.

CLL can also result in the destruction of red blood cells, leaving you with too few of them. This is called cytopenia.

Like most cancers, early detection and treatment can help control the disease or eliminate it from your body.

This content was last modified on August 11, 2007 .
Latest Chronic Lymphocytic Leukemia News
Green tea ingredient may fight incurable leukemia

June 4, 2009 — NEW YORK (Reuters Health) - A chemical found in green tea may shrink lymph nodes and reduce white blood cell counts in patients with chronic lymphocytic leukemia (CLL), a new study in the Journal of Clinical Oncology shows.

FDA advisers back Glaxo, Genmab cancer drug

May 29, 2009 — ORLANDO, Florida (Reuters) - A small trial of Arzerra, being developed by GlaxoSmithKline Plc and Genmab for treating chronic lymphocytic leukemia, indicated benefits sufficient for U.S. approval, an advisory committee to regulators said on Friday.

FDA staff questions data on leukemia drug

May 27, 2009 — WASHINGTON (Reuters) - U.S. drug reviewers questioned whether a proposed leukemia drug from GlaxoSmithKline PLC and Genmab provides enough benefit to warrant approval, documents released on Wednesday said.

Select news items provided by Reuters Health